This month the two ends of the Canadian cannabis market moved at once: the export lane most producers are banking on repriced downward, and the Canada Revenue Agency stopped waiting to be paid. Both point at the same pressure — and the same way off it.
The number that moved
Germany — the export market most Canadian producers are counting on for the exit — just repriced. Over the tracked year, median pharmacy flower fell 31% to €5.95/g, the cost per 10 mg of THC dropped 36%, and average potency climbed to 26% (Forbes, July 8, 2026). The highest-value medical channel on earth is now running the same play as the Canadian rec market — cheaper grams, higher THC, commodity logic. The exit is compressing before most producers have reached it.
The signal
At home, the excise story of the last six weeks was enforcement, not reform. On June 17, Entourage Health filed for CCAA owing its secured lender ~$240.1M, into a court-ordered wind-down. Six days later, Blizza Brands filed a notice of intent — but the trigger is the tell: the CRA had already cancelled its excise licence and destroyed its inventory over roughly $599K in owed duty.
That is new. The CRA has moved from passively letting excise arrears accrue — $200M+ outstanding sector-wide — to actively cancelling licences and destroying product before insolvency. And it is collecting: the provinces project more than $800M in federal excise transfers for 2026/27, part of $5.4B in cannabis tax taken since legalization — from an industry where about one in seven producers turns a profit.
The structural read
The two stories are the same story. In Germany, commodity flower is being competed to the floor; in Canada, the floor is the tax. Both punish the same thing — low value per gram — and both reward the same escape.
Entourage, Blizza, and the four Canadian producers that filed before them this year did not fail because they made bad hash. They failed because they made cheap grams, and the flat dollar ate them — and no amount of volume out-runs a flat dollar. It can only be escaped by changing what the gram becomes.
The math makes it concrete. At today's ~$1.51/g weighted-average flower, the $1 duty is 66% of the sale. Move that same biomass onto the extract basis — hash and rosin are taxed per milligram of THC, not on the flat dollar — and a standard 4★ cold-water hash gram at ~$12 carries about $5.50 of duty: 46% of a gram worth several times the flower. Climb to 6★ cold-water hash or a documented, medical-grade extract and it falls further still. The tax never changed. The product did.
Germany's repricing sharpens the point: as commodity medical flower compresses toward €4.50–6/g, the premium, EU-GMP-documented lane still clears north of €11/g. Notice what the survivors are buying — when Emblem absorbed Ayurcann's lines out of creditor protection on June 8, it bought processing capacity and product mix, not more flower. Value per gram is the only lever either market responds to — and the only way to raise it is to refine.
The operator move
1. Treat excise as a treasury line, not a compliance one. Model your duty per gram, per product — the flat dollar on flower and the per-mg rate on extracts produce completely different effective rates, and your product mix is a lever you control.
2. Assume the CRA is now an active creditor. The Blizza precedent means an excise-licence dispute can end in cancellation and destroyed inventory, not just accruing interest.
3. Build the documented-premium lane before you need it. Germany's compression is closing the commodity exit; the EU-GMP, recipe-driven, traceable lane is where durable margin sits — and processing capacity, not flower, is the constraint.
From the desks
The Cannabis Council of Canada is still pressing Ottawa to scrap the $1/g floor for a straight 10% ad valorem — the fix the House Finance Committee recommended in 2024, still unadopted after Budget 2025. South of the border the pattern rhymes: Whitney Economics puts the cost of the US 280E structure at $2.24B in excess federal tax on operators in 2025 alone, and Michigan's new 24% wholesale excise tax is now named, on the record, as a direct cause of TerrAscend's Michigan receivership. Different tax, same mechanism: a levy indexed to anything other than profit breaks producers at scale. The remedy the burden studies keep circling and never close — it isn't only a better rate. It's a better gram.
One number to run yourself
One biomass, four tax rates — set entirely by what you choose to make:
| The same trim & biomass, sold as… | Effective excise |
|---|---|
| Dried flower (~$1.51/g) | ~66% |
| 4★ cold-water hash (~$12/g) | ~46% |
| 6★ cold-water hash (~$24/g) | ~29% |
| Medical / EU-GMP rosin (export band) | ~21% |
The excise floor punishes low value per gram. The entire point of refinement is to raise it.
The Abzu Refinery is the cold-water trichome refinery — a closed, sealed-vessel machine with no open tank, no ice, no bags, one operator — carrying trim and biomass in a single controlled environment from separation to collection, into graded, documented solventless concentrate and recovering better than 90% of available trichome. It's how a commodity gram becomes the gram that escapes the floor.
Sources. Forbes (German pharmacy pricing, Jul 8 2026); StratCann & Insolvency Insider (Entourage CCAA, Blizza NOI, provincial excise transfers); Cannabis Business Times & cann.dev (Whitney Economics 280E; TerrAscend); Canada.ca (excise duty rates); International Cannabis Business Conference (reform advocacy). Effective-rate figures use canonical Abzu reference numbers and current, sourced market prices; confirm your own position against your excise filings. Public market analysis — not tax advice.